Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements
Mené sur 122 patients atteints d'un cholangiocarcinome de stade localement avancé ou métastatique et présentant des altérations du gène FGFR2, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'infigratinib, après l'échec d'un traitement par gemcitabine
Although they are the second leading cause of primary liver cancer after hepatocellularcarcinoma, biliary tract cancers are rare tumours (excluding endemic areas in Asia),with less than six new cases per 100 000 people each year. Biliary tract cancers are classified into three subtypes on the basis of their anatomicalorigin: intrahepatic cholangiocarcinoma (the incidence of which is increasing in theUSA and Europe), extra-hepatic cholangiocarcinoma, and gallbladder carcinoma. Prognosisfor patients with biliary tract cancers is poor (5-year overall survival <20%), mainlydue to late diagnosis, frequently at an advanced stage (in around 65% of patients).
The Lancet Gastroenterology and Hepatology , commentaire, 2020